Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression

European Journal of Cancer

Volumn 49, Issue 7, 2013, Pages 1715-1724

  Oguro, Toshiki ^a   Ishibashi, Kei ^a   Sugino, Takashi ^a   Hashimoto, Koichi ^a   Tomita, Shintaro ^a   Takahashi, Norio ^a   Yanagida, Tomohiko ^a   Haga, Nobuhiro ^a   Aikawa, Ken ^a   Suzutani, Tatsuo ^a   Yamaguchi, Osamu ^a   Kojima, Yoshiyuki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

IL 6; IL 6 receptor; Interferon; Renal cell carcinoma; SOCS3; Tocilizumab

Indexed keywords

ALPHA INTERFERON; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOCILIZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL INVASION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERONS; INTERLEUKIN-6; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; RECEPTORS, INTERLEUKIN-6; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876117522     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.11.038     Document Type: Article

References (39)

1. S.H. Landis, T. Murray, S. Bolden, and P.A. Wingo Cancer statistics, 1999 CA Cancer J Clin 49 1 1999 8 31 1 (Pubitemid 29094959)
2. W.Y. Siow, S.K. Yip, and L.G. Ng Renal cell carcinoma: incidental detection and pathological staging J R Coll Surg Edinb 45 5 2000 291 295
3. K.H. Tsui, O. Shvarts, and R.B. Smith Renal cell carcinoma: prognostic significance of incidentally detected tumors J Urol 163 2 2000 426 430 (Pubitemid 30060485)
4. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2 2007 115 124 (Pubitemid 46089672)
5. R.J. Motzer, M.D. Michaelson, and J. Rosenberg Sunitinib efficacy against advanced renal cell carcinoma J Urol 178 5 2007 1883 1887 (Pubitemid 47538608)
6. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2 2007 125 134 (Pubitemid 46089673)
7. C. Coppin, C. Kollmannsberger, L. Le, F. Porzsolt, and T.J. Wilt Targeted therapy for advanced renal cell cancer (RCC): a cochrane systematic review of published randomised trials BJU Int 108 10 2011 1556 1563
8. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 9605 2007 2103 2111 (Pubitemid 350296300)
9. S. Tochizawa, N. Masumori, and Y. Yanai Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines Biomed Res 29 6 2008 271 278
10. M. Niwakawa, K. Hashine, and R. Yamaguchi Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma Invest New Drugs 30 3 2012, Jun 1046 1054
11. S. Tomita, K. Ishibashi, and K. Hashimoto Suppression of SOCS3 increases susceptibility of renal cell carcinoma to interferon-alpha Cancer Sci 102 1 2011 57 63
12. R. Starr, T.A. Willson, and E.M. Viney A family of cytokine-inducible inhibitors of signalling Nature 387 6636 1997 917 921 (Pubitemid 27289594)
13. P.C. Heinrich, I. Behrmann, and S. Haan Principles of interleukin (IL)-6-type cytokine signalling and its regulation Biochem J 374 Pt 1 2003 1 20 (Pubitemid 37046923)
14. N. Nishimoto, K. Yoshizaki, and N. Miyasaka Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial Arthritis Rheum 50 6 2004 1761 1769 (Pubitemid 38725087)
15. T. Imagawa, S. Yokota, and M. Mori Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis Mod Rheumatol 22 1 2012 109 115
16. N. Nishimoto, Y. Kanakura, and K. Aozasa Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease Blood 106 8 2005 2627 2632 (Pubitemid 41510733)
17. H. Ito, M. Takazoe, and Y. Fukuda A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease Gastroenterology 126 4 2004 989 996 discussion 947 (Pubitemid 38451170)
18. C.E. Falkensammer, M. Thurnher, N. Leonhartsberger, and R. Ramoner C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival BJU Int 107 12 2010 1893 1898
19. X. Zhang, and R. Peck Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis Expert Rev Clin Pharmacol 4 5 2011 539 558
20. A. Plonowski, A.V. Schally, and A. Nagy Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238 Cancer Res 60 11 2000 2996 3001 (Pubitemid 30395826)
21. S. Shinriki, H. Jono, and K. Ota Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma Clin Cancer Res 15 17 2009 5426 5434
22. S. Ramsey, M. Aitchison, J. Graham, and D.C. McMillan The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer BJU Int 102 1 2008 125 129 (Pubitemid 351799440)
23. A. Yoshimura, T. Naka, and M. Kubo SOCS proteins, cytokine signalling and immune regulation Nat Rev Immunol 7 6 2007 454 465 (Pubitemid 46834848)
24. M.M. Song, and K. Shuai The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities J Biol Chem 273 52 1998 35056 35062 (Pubitemid 29028206)
25. P.C. Heinrich, J.V. Castell, and T. Andus Interleukin-6 and the acute phase response Biochem J 265 3 1990 621 636 (Pubitemid 20053863)
26. E. Nemeth, E.V. Valore, and M. Territo Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein Blood 101 7 2003 2461 2463 (Pubitemid 36857598)
27. T. Kishimoto Interleukin-6: from basic science to medicine-40 years in immunology Annu Rev Immunol 23 2005 1 21 (Pubitemid 40563163)
28. R.J. Motzer, J. Bacik, B.A. Murphy, P. Russo, and M. Mazumdar Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 1 2002 289 296 (Pubitemid 34032623)
29. M. Takahashi-Tezuka, Y. Yoshida, and T. Fukada Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase Mol Cell Biol 18 7 1998 4109 4117 (Pubitemid 28287934)
30. M. Itoh, Y. Yoshida, and K. Nishida Role of Gab1 in heart, placenta, and skin development and growth factor- and cytokine-induced extracellular signal-regulated kinase mitogen-activated protein kinase activation Mol Cell Biol 20 10 2000 3695 3704 (Pubitemid 30243915)
31. N.A. Cacalano, D. Sanden, and J.A. Johnston Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras Nat Cell Biol 3 5 2001 460 465 (Pubitemid 32422081)
32. D.P. Jackson, D. Watling, and N.C. Rogers The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line Melanoma Res 13 3 2003 219 229 (Pubitemid 36683763)
33. D. Shang, Y. Liu, N. Ito, T. Kamoto, and O. Ogawa Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance Cancer Sci 98 8 2007 1259 1264 (Pubitemid 46993547)
34. Z. Chen, P.S. Malhotra, and G.R. Thomas Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer Clin Cancer Res 5 6 1999 1369 1379 (Pubitemid 29282941)
35. M. Trikha, R. Corringham, B. Klein, and J.F. Rossi Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence Clin Cancer Res 9 13 2003 4653 4665 (Pubitemid 37323267)
36. D.S. Hong, L.S. Angelo, and R. Kurzrock Interleukin-6 and its receptor in cancer: implications for translational therapeutics Cancer 110 9 2007 1911 1928 (Pubitemid 350036849)
37. S.A. Duffy, J.M. Taylor, and J.E. Terrell Interleukin-6 predicts recurrence and survival among head and neck cancer patients Cancer 113 4 2008 750 757
38. S. Negrier, D. Perol, and C. Menetrier-Caux Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie J Clin Oncol 22 12 2004 2371 2378 (Pubitemid 41115394)
39. A.J. Montero, C.M. Diaz-Montero, and R.E. Millikan Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival Ann Oncol 20 10 2009 1682 1687